Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035607
Status:
COMPLETED
Last Update Posted:
2013-05-13
First Post:
2002-05-03
Brief Title:
Chemotherapy Related Anemia
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Randomized Open-label Multicenter Study of Subcutaneous and Intravenous Administration of Darbepoetin Alfa Novel Erythropoiesis Stimulating Protein NESP for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is investigating darbepoetin alfa for the treatment of anemia in patients with non-myeloid cancers who are receiving chemotherapy Darbepoetin alfa is a recombinant protein that stimulates the production of red blood cells In this study darbepoetin alfa will be administered as either an injection under the skin subcutaneously or directly into a vein intravenously
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None